Shared on08 Aug 25Fair value Decreased 24%
The significant drop in biote’s net profit margin combined with a sharply higher future P/E suggests deteriorating profitability and a less attractive valuation outlook, leading to the consensus analyst price target being revised down from $6.40 to $4.98. What's in the News Biote Corp.
Shared on23 Apr 25Fair value Decreased 6.85%
AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.1%.
Shared on17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 1.06%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Increased 33%
AnalystConsensusTarget has decreased revenue growth from 16.9% to 8.9%, decreased profit margin from 15.5% to 8.7% and increased future PE multiple from 10.9x to 17.8x.